Skip to main content
. 2006 Jun 13;4:24. doi: 10.1186/1479-5876-4-24

Figure 3.

Figure 3

Tumor-specific protective immunity in long-term survivor mice. IL-21 + IL-2 treated mice that survived disease free for 150 days were rechallenged with B16F10 (5 × 105) or 3LL(5 × 104) tumor cells. All 3LL challenged mice (4/4) exhibited mean tumor growth to ≥ 200 mm2 by day 32; all B16F10 challenged mice (5/5) were protected. Naïve mice challenged with the same B16F10 (5/5) or 3LL (5/5) tumor cells had rapid mean tumor growth to ≥ 200 mm2 by day 25.